AR122044A1 - Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus - Google Patents

Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus

Info

Publication number
AR122044A1
AR122044A1 ARP210101267A ARP210101267A AR122044A1 AR 122044 A1 AR122044 A1 AR 122044A1 AR P210101267 A ARP210101267 A AR P210101267A AR P210101267 A ARP210101267 A AR P210101267A AR 122044 A1 AR122044 A1 AR 122044A1
Authority
AR
Argentina
Prior art keywords
treatment
parapoxvirus
conditioning
coronavirus infections
coronavirus
Prior art date
Application number
ARP210101267A
Other languages
English (en)
Inventor
Paulsen Daniela Dr
Birkmann Alexander Dr
Lischka Peter Dr
Pfaff Tamara Dr
Zimmermann Holger Dr
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of AR122044A1 publication Critical patent/AR122044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al tratamiento de infecciones por coronavirus y a la preparación de sujetos para tal infección mediante la administración de un parapoxvirus. Este tratamiento tiene el propósito de asistir al sistema inmunológico en el combate del virus y de esta forma prevenir y aliviar los síntomas de la enfermedad por coronavirus.
ARP210101267A 2020-05-08 2021-05-10 Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus AR122044A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20173670.9A EP3906970B1 (en) 2020-05-08 2020-05-08 Parapoxvirus for conditioning and treatment of coronavirus infections

Publications (1)

Publication Number Publication Date
AR122044A1 true AR122044A1 (es) 2022-08-03

Family

ID=70680251

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101267A AR122044A1 (es) 2020-05-08 2021-05-10 Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus

Country Status (27)

Country Link
US (1) US20220401553A1 (es)
EP (2) EP3906970B1 (es)
JP (1) JP2023525269A (es)
KR (1) KR20230008703A (es)
CN (1) CN115003329A (es)
AR (1) AR122044A1 (es)
AU (1) AU2021267148A1 (es)
BR (1) BR112022022635A2 (es)
CA (1) CA3173998A1 (es)
CR (1) CR20220569A (es)
DK (1) DK3906970T3 (es)
EC (1) ECSP22085708A (es)
ES (1) ES2926807T3 (es)
HR (1) HRP20221110T1 (es)
HU (1) HUE060482T2 (es)
IL (1) IL297983A (es)
LT (1) LT3906970T (es)
MX (1) MX2022013979A (es)
PE (1) PE20230459A1 (es)
PL (1) PL3906970T3 (es)
PT (1) PT3906970T (es)
RS (1) RS63635B1 (es)
SI (1) SI3906970T1 (es)
TW (1) TWI796688B (es)
UY (1) UY39206A (es)
WO (1) WO2021224503A1 (es)
ZA (1) ZA202210585B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114940707B (zh) * 2022-04-19 2023-07-18 中国医学科学院病原生物学研究所 Rae1-Nup98特异性结合多肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE500320T1 (de) * 2003-08-18 2011-03-15 Amsterdam Inst Of Viral Genomics B V Coronavirus, nukleinsäure, protein, verfahren zur erzeugung der impfstoffe, medikamente und diagnostika
CN1984666A (zh) * 2004-07-13 2007-06-20 爱库里斯股份有限两合公司 与其他抗病毒剂联合治疗hiv/aids的副痘病毒
TW201919675A (zh) 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
CN112867505B (zh) * 2018-09-20 2024-10-01 勃林格殷格翰动物保健有限公司 经修饰的pedv刺突蛋白

Also Published As

Publication number Publication date
ZA202210585B (en) 2023-06-28
WO2021224503A1 (en) 2021-11-11
EP4146262A1 (en) 2023-03-15
IL297983A (en) 2023-01-01
LT3906970T (lt) 2022-10-10
EP3906970A1 (en) 2021-11-10
US20220401553A1 (en) 2022-12-22
CN115003329A (zh) 2022-09-02
PT3906970T (pt) 2022-08-23
PE20230459A1 (es) 2023-03-10
JP2023525269A (ja) 2023-06-15
CA3173998A1 (en) 2021-11-11
CR20220569A (es) 2023-01-10
DK3906970T3 (da) 2022-09-12
PL3906970T3 (pl) 2022-10-24
ES2926807T3 (es) 2022-10-28
HRP20221110T1 (hr) 2022-11-25
RS63635B1 (sr) 2022-10-31
SI3906970T1 (sl) 2022-11-30
EP3906970B1 (en) 2022-07-06
KR20230008703A (ko) 2023-01-16
HUE060482T2 (hu) 2023-03-28
BR112022022635A2 (pt) 2023-05-02
TWI796688B (zh) 2023-03-21
AU2021267148A1 (en) 2022-12-01
ECSP22085708A (es) 2022-12-30
UY39206A (es) 2021-07-30
TW202207980A (zh) 2022-03-01
MX2022013979A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
CO2021008988A2 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
ECSP22085708A (es) Uso de parapoxvirus para el acondicionamiento y tratamiento de infecciones por coronavirus
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
CO6761399A2 (es) Composiciones y métodos de vacuna del virus tipo 1b de diarrea viral bovina
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
BRPI1006266A2 (pt) adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato
RU2015134421A (ru) Применение левоцетиризина и монтелукаста при лечении травматических повреждений
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
ES2544153B1 (es) Uso de un hidrolizado de caseína como agente antiviral
CL2020001353A1 (es) Pirazolopirimidinas que tienen actividad contra el vsr.
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero
CL2018003270A1 (es) Una composición farmacéutica que comprende ácido carboxílico para tratar y prevenir congestión nasal.
Yamamoto Pandemic control measures
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
Teluguakula et al. Neutrophils as possible therapeutic targets in severe influenza pneumonia
BR112019002125A2 (pt) composição de comprimidos de alta carga de fármacos para o tratamento do hiv
JEONG et al. Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease
CL2023001196A1 (es) Composición farmacéutica adecuada para administración vaginal en forma de óvulos y uso de la misma.
Zhang et al. Curative effect observation of ju-hong tan-ke liquid in treatment of patients with anemofrigid (or mixing with Damp) Cough
Shaposhnik et al. Modern trends in pharmacotherapy of diseases caused by influenza A.